Helus PharmaHELP +7.82%22 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 736 Biotechnology companies, Helus Pharma ranks worse than 135869.43% on this metric.
The historical rank and industry rank for Helus Pharma's Gross Margin % or its related term are showing as below:
During the past 6 years, the highestGross Margin % of Helus Pharma was 23.14%. The lowest was 23.14%. And the median was 23.14%.
HELP's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Helus Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Helus Pharma was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Helus Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Helus Pharma Gross Margin % Related Terms
Helus Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Helus Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HELP vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Helus Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Helus Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Helus Pharma (HELP) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Helus Pharma and its competitors. Over the past decade, Helus Pharma's Gross Margin % has ranged from 23.14 to 23.14. According to the industry distribution chart, Helus Pharma ranks #999999 out of 736 companies in the Biotechnology industry.
Is Helus Pharma's Gross Margin % too high?
Helus Pharma's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 23.14 to a high of 23.14. Based on the distribution chart, Helus Pharma ranks #999999 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #999999 out of 736 companies for Gross Margin %. This places Helus Pharma in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Helus Pharma's own Gross Margin % has ranged from 23.14 to 23.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Helus Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Helus Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Helus Pharma (HELP), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score
Get the complete analysis for HELP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HELP has been successfully added to your 
